Lupin Pharmaceuticals has received FDA approval for Suprax (Cefixime) capsules 400mg and will initiate the shipment of the product shortly.
The approval will expand Lupin's range of Suprax dosage forms available to treat the approved indications in appropriate patients.
At present Suprax is available as 100mg/5ml and 200mg/5ml suspensions as well as 400mg tablets.
Lupin Limited group president and executive director Nilesh Gupta said the new dosage form will add to the company's growing Suprax franchise and gives health care providers and patients a new formulation to treat the indicated infections.
"The approval of SUPRAX capsules is one more example of our ongoing commitment to serving our customers and addressing their needs," Gupta added.
